<DOC>
	<DOCNO>NCT01126814</DOCNO>
	<brief_summary>This Phase I-II study evaluate toxicity efficacy imatinib combine mitoxantrone , etoposide high-dose cytarabine reinduction therapy relapse refractory AML . Patients treat initially 200 mg dose imatinib ; tolerate , imatinib dose escalate subsequent cohort 300 mg 400 mg. Once recommend dose determine , remain patient treat dose , evaluate antileukemic activity regimen . Patients achieve complete remission receive consolidation therapy imatinib combine high-dose cytarabine mitoxantrone , follow maintenance imatinib .</brief_summary>
	<brief_title>A Study Imatinib With Reinduction Chemotherapy Using Mitoxantrone , Etoposide Cytarabine Patients With Relapsed/Refractory C-kit Positive ( AML ) Acute Myeloid Leukemia</brief_title>
	<detailed_description>Induction therapy : - Imatinib 200-400 mg p.o . daily x 10 day , Days 1-10 ( see dose escalation scheme Section 5.4 ) . - Mitoxantrone 10 mg/m2 daily x 5 day , Days 4-8 . - Etoposide 100 mg/m2 daily x 5 day , Days 4-8 . - Cytarabine 1.5 grams/m2 q12h x 4 dos , Days 9-10 ( patient age 60 year , 1.0 gram/m2 ) . Only one induction course permit . Only patient achieve CR proceed consolidation maintenance . Consolidation therapy , maximum 2 cycle ( patient achieve CR ) : - Imatinib 200-400 mg p.o . daily x 8 day , Days 1-8 ( see dose escalation scheme Section 5.4 ) . - Mitoxantrone 12 mg/m2 daily x 2 day , Days 4-5 . - Cytarabine 3 grams/m2 q12h x 6 dos , Days 4,6,8 . For patient age 60 year , dose reduce 1.5 grams/m2 . Maintenance therapy ( patient still CR end consolidation ) : Imatinib 600 mg p.o . daily , relapse toxicity ( see dose modification criterion Section 5.6.6 ) . Patients must receive least one consolidation cycle permit proceed maintenance therapy ( see Section 5.6 detail ) . Maintenance therapy imatinib provide maximum period 1 year . Dose escalation scheme : Imatinib use induction consolidation one follow dose level : Level -1 100 mg daily Level 1 200 mg daily Level 2 300 mg daily Level 3 400 mg daily</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>AML , subtypes except APL . Prior induction therapy consist cytarabine 100200 mg/m2 plus anthracycline . One following : persistent leukemia induction therapy . relapse within two year achieve complete remission induction therapy . Any consolidation therapy acceptable , include stem cell transplantation . At least 10 % bone marrow blast , biopsy confirm extramedullary disease . Positivity ckit ( CD117 ) least 30 % blast measure flow cytometry . Aged 1865 . ECOG performance status &lt; 3 ( see Appendix I ) . No chemotherapy within previous four week , hydroxyurea control count . If hydroxyurea use , must stop least 24 hour prior start imatinib . Able give informed consent . Active uncontrolled infection . Active CNS leukemia . Serum creatinine &gt; 200 umol/L . Serum bilirubin &gt; 1.5 x ULN , AST ALT &gt; 2x ULN . Left ventricular ejection fraction &lt; 50 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Gleevec</keyword>
	<keyword>c-kit</keyword>
	<keyword>aml</keyword>
</DOC>